Abstract
Introduction
Vulvar intraepithelial neoplasia (VIN) is a condition in which changes occur in the skin covering the vulva of female external genitalia from one that is benign into one that has the potential to become invasive, affecting all tis-DOI: 10 .1159/000500469 sues of the pudendal region of the pelvic floor. In 1986, the International Society for the Study of Vulvovaginal Disease (ISSVD) devised a classification system for VIN, which was updated in 2004 and remains the most commonly used system in the literature [1] . Pre-invasive abnormalities in the vulval tissue are categorised as VIN 1-3, depending on the level of dysplasia present, which is similar to the current grading of cervical intraepithelial neoplasia (CIN), a related and often coincidental finding during clinical examination and diagnosis. It is widely believed that VIN 1 has a low malignant potential and is not a precursor of VIN 2 or 3, which have high malignant potential, often presenting as or developing into invasive squamous cell carcinoma.
Since the 1980s, the incidence of VIN has increased in several countries and in particular within the younger female population [2] . Despite this, VIN remains a relatively uncommon condition, with an unclear aetiology. Younger women tend to have the "usual-type" VIN that is characterised by previous or existing exposure to human papillomavirus (HPV), whereas older women tend to have the "unusual-type" VIN, which is not related to HPV exposure, but is related to chronic dermatological conditions, in particular vulvar lichen sclerosis [3] . The symptoms reported by patients with VIN are itching, burning, dyspareunia and the appearance of leucoplakic patches in any part of the vulva, but often patients are asymptomatic and suspected VIN is often observed during the annual sexual health examination. Emerging evidence suggests that the type of VIN and recurrence of disease may be related to the presence of viruses other than HPV, such as human immunodeficiency virus (HIV), or in immunocompromised patients, suggesting that immunomodulation may have a prognostic effect in some, but not all, forms of VIN [4] .
Due to the multifactorial and heterogeneous nature of VIN, there is no single characteristic or pathognomonic feature that can facilitate the diagnosis of VIN. If VIN is suspected, visual inspection of the vulva and surrounding tissues (cervix, vagina, perineum, anus, rectum, and gluteal folds) with vulvoscopy aids the collection of the vulval biopsy, and confirmation of disease is made by histological examination. VIN in more than one part of the vulval tissue is defined as multifocal, whilst lesions in more than one genital site is defined as being multicentric disease. In some series, additional areas of VIN have been found in 80% of the areas adjacent to the primary lesion [5] . This high rate of concurrent disease is mostly characteristic of younger women.
There are numerous standard treatments for VIN and for the prevention of VIN 2/3 progressing to vulval cancer [6] [7] [8] [9] . The gold standard treatment for high-grade vulval intraepithelial lesions is surgery (either localised or radical excision) or laser ablation [10] . Alternatively, immune modulators such as imiquimod [11] [12] [13] can be used as adjunctive therapy, although the efficacy and side effects of this combined treatment remain undetermined.
The primary aim of this study was to determine the impact of lesion focality and centricity at VIN presentation in relation to patient outcome and disease recurrence. In particular, the effectiveness of different treatment modalities on disease-free duration, disease recurrence, and failure rates, based on focality and centricity of the disease at presentation, was studied. In addition, how VIN presentation and outcomes varied with immune status, specifically HIV status, was determined.
Materials and Methods
For further details, see the online supplementary material (see www.karger.com/doi/10.1159/000500469 for all online suppl. material) (Fig. 1) .
Results
Histological diagnosis confirmed the presence of VIN in all patients, with 24 women having unifocal disease and 54 having multifocal disease. Furthermore, 30 patients had unicentric disease and 48 had multicentric disease (Table 1) , and in 12 cases, the number and positions of lesions were not recorded. Since multiple combinations are possible at diagnosis, these possible combinations are presented together in Table 1 .
At the time of presentation, 61% of the HIV-patients (n = 15) were smokers whilst only 23% of the HIV+ patients (n = 75) were smokers. Although those who smoked in the HIV+ group smoked less than 20 cigarettes/day, some of the HIV-group (6%) smoked more than 20 cigarettes/day. Analysis showed that smoking was not a confounding factor for later analyses for disease recurrence in either group.
The HIV+ subgroup presented with fewer symptoms than the HIV-group, and more patients were asymptomatic (Fig. 2a) . The presence of a lesion, pruritus, pain, or a combination of these symptoms was similar in both groups, although "soreness" was only reported in the HIV-group. The type of lesion present and initially diagnosed was similar in both groups, with 76% of the HIV-group and 93% of the HIV+ group, respectively, presenting with VIN 3 or invasive disease ( thermore, 60% of HIV+ patients had a coincidental diagnosis of CIN and or vaginal intraepithelial neoplasia (VAIN), in contrast to only 28% of the HIV-patients (Fig. 2c ). The majority of HIV+ patients (87%) had a previous diagnosis of CIN/VAIN, compared to only 48% of the HIV-patients (Fig. 2c) .
Nine different management plans were put in place on initial presentation (Table 2) , with 39 patients being managed conservatively, and of this group 1 patient went on to have examination under anaesthesia and 1 went on to develop invasive disease. Laser therapy as initial treatment was used on 23 patients and of these, 7 had recurrent disease within a year and 15 within 2 years. Diathermy ablation was used to treat 12 patients, and 3 patients had diathermy excision. Only 1 patient in our cohort who had imiquimod therapy relapsed and had recurrence of disease; in this case the patient did not require any further treatment (Table 2) . One patient had radiotherapy (following diagnosis of invasive cancer), 1 was referred to a cancer centre, and 1 had a vulvectomy. In all cases, a recurrence of disease occurred (Table 2) . Only 3 (20%) of the HIV+ patients and 30 (38.5%) of the HIV-patients were disease free in December 2017, whilst 12 patients (13.3%) were lost to follow-up. One patient died of Hodgkin's lymphoma, 3 died of causes that were not recorded, and 2 developed invasive vulval carcinoma (Table 2) . Of the 78 patients who had detailed notes available, 12 out of the 15 HIV+ group (80%) and 30 out of the 63 remaining HIV-patients (47.6%) had recurrent disease (Fig. 3) . Bi- nomial logistic regression indicated that none of the clinical interventions were effective in preventing recurrence of disease and that none of the symptoms and signs at diagnosis except multicentricity (p = 0.01) and multifocality (p = 0.001) were significantly linked to disease recurrence (p < 0.0001). CD4+ lymphocyte count (p = 0.903) and HIV status (p = 0.432) were not significantly associated with disease recurrence in the logistic analysis.
An analysis of the effect of centricity and focality on the time to disease recurrence indicated that both factors had a significant effect on the rate of recurrence; multicentricity was more rapid than unicentricity (p = 0.006; Fisher's exact test) and multifocality was more rapid than unifocality (p < 0.0001; Fisher's exact test) in relation to disease recurrence and progression (Table 1) . A total of 31 patients presented with multifocal and multicentric disease and 23 presented with multifocal and unicentric disease. It was these patient groups who had a significantly shorter time to disease recurrence (p = 0.0005; Table 1 ). The average time to disease recurrence in HIV+ patients was 3.2 years, compared to 5.4 years in the HIV-patients, with 73% of HIV+ patients presenting with multifocal disease compared to only 61% of HIV-patients.
In HIV+ patients, viral load and time to disease recurrence were not related (Fig. 4a) , but a significant positive correlation (p = 0.02, r 2 = 0.665) was observed between CD4+ lymphocyte count at diagnosis and time to recurrence (Fig. 4b) . 
Discussion
The data presented here show that both VIN focality and centricity at initial diagnosis have a significant effect on both interval to recurrence and final outcome for the patient diagnosed with VIN, and despite the nine different treatment options used, only 12 women were disease free after 5 years. Recurrence within 2 years was highest overall in those women with multifocal/multicentric disease with 7% of this cohort developing invasive forms of vulval cancer. This degree of effect has been reported previously by others [14] [15] [16] [17] [18] , suggesting that both where and how many lesions there are at presentation should be uppermost in the clinician's mind.
The majority of women presented with VIN 2/3, and the main concern with VIN 2/3 is its potential to progress to vulval cancer. Although a woman's risk of developing cancer of the vulva by the age of 75 years varies between countries, and ranges from 0.01 to 0.28%, in some studies the progression to invasive vulval cancer with untreated high-grade VIN may be as high as 9% [19] . For treated lesions, this rate is between 2 and 5% [2] . An increase in vulval cancer in women under the age of 50 years has been increasingly documented [6, 20] and has been linked to an increasing incidence of VIN in younger women. This has been attributed to infection with HPV, smoking, or poor immunological status, especially in HIV+ women [4, 14, 21] . Observations made herein indicate that although there is no real difference in VIN recurrence between HIV+ and HIV-women, the rate to recurrence is higher in HIV+ women. The suggestion here is that HIV+ women are particularly sensitive to the development and 
1 Follow-up means a patient with chronic VIN but no progression of disease and therefore on long-term observation only; re-treatment/EUA indicates that a different treatment modality was applied either after evaluation under anaesthesia (EUA) or independent of re-diagnosis; invasive means VIN had progressed to vulval cancer. recurrence of VIN and ultimately vulval cancer. In this study, 17% of the patient group were HIV+, which was significantly higher than that of the general female population of London at the time, where only 0.1% were known to be HIV+. This suggests that VIN may occur as a consequence of HIV infection, possibly through the loss of CD4+ lymphocytes but not because of increased viral load (Fig. 3) . However, because of the small numbers of patients that had a viral load or HIV positivity test in this study, firm conclusions on this cannot be made at this time, even though immunocompromised patients are at a higher risk of recurrent disease [22] .
Symptoms at presentation were very similar in both HIV+ and HIV-patients, with 60% presenting with a lesion alone or alongside other symptoms including pruritus and vulval pain. We noted that a greater number of HIV+ patients (93%) had the more advanced VIN 3 disease compared to only 76% of the HIV-patients, suggesting that the presumably higher CD4+ lymphocyte count in the HIV-patients provides suitable immune surveillance and prevention of conversion to malignancy. This is supported by the observation that the majority (85%) of HIV+ patients had a coincidental or previous diagnosis of CIN/VAIN, whilst CIN/VAIN were only diagnosed in < 50% of HIV-patients. These data suggest that HIV+ patients have a greater propensity to the development of such neoplasms.
Treatment modality did not seem to have any significant effect of outcome. This is similar to previous studies where radical vulvectomy or combination therapy had no significant effect on patient outcomes [7, 8, 23] . Radical vulvectomy in our cohort did not seem to show any improvement over any other treatment modality, suggesting that a conservative approach in younger women is probably an acceptable treatment option.
Conclusions
Multicentricity and multifocality of VIN lesions at the time of diagnosis should be determined and the presence of both parameters act as a warning for the gynaecologist/ gynaecology oncologist/dermatologist to initiate close monitoring for disease recurrence. We believe that after further, larger studies, the presence of both parameters may eventually be used to predict those women at high risk of VIN recurrence and progression to vulval cancer, which may influence and guide treatment choices.
Immunosuppressed groups and HIV+ patients are more likely to present with multifocal and more advanced disease (VIN 2/3), and as such, HIV+ VIN patients with multifocal and/or known immunosuppression (demonstrated by a low CD4+ lymphocyte count) should be regarded as "high-risk" patients and treated accordingly. Such groups may be appropriately managed in clinics with access to multidisciplinary services, including dermatologists, whose experience with the use of imiquimod may change the treatment choice.
Key Message
Multicentricity and multifocality of VIN lesions should be considered as poor prognostic indicators at diagnosis.
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